Management &
Board of Directors
At Hervolution, we challenge biotechnology as we know it by shifting the paradigm in cancer immunotherapy. We have established a great team of scientists, advisors and entrepreneurs with long-standing experience to drive our research every day.
Dr. Coleman is a distinguished scientist, entrepreneur, biotech CEO, and company builder who brings a wealth of experience in driving ground-breaking platform technologies from initial innovation to Phase 3 clinical trials and beyond. Coleman’s specific track record is in early- and late-stage development of viral-based vaccines and therapeutics, raising over $120 million in public and private financing. Coleman has a keen ability to maximize shareholder value through creative and thoughtful management of multi-asset / multi-disciplary pipelines.
Dr. Holst is the founder of Hervolution and has a long-standing experience within immunology and has made pivotal discoveries in these fields. He has taken virus-vectored vaccines further by developing the first clinically effective genetic adjuvants. Peter Holst’s prior inventions are in clinical trials and licensed to GSK.
Dr. Holst is the founder of Hervolution and has a long-standing experience within immunology and has made pivotal discoveries in these fields. He has taken virus-vectored vaccines further by developing the first clinically effective genetic adjuvants. Peter Holst’s prior inventions are in clinical trials and licensed to GSK.
At Hervolution, we challenge biotechnology as we know it by shifting the paradigm in cancer immunotherapy. We have established a great team of scientists, advisors and entrepreneurs with long-standing experience to drive our research every day.
Biotech CEO, Company Builder, Inventor. Creative and highly motivated entrepreneur with demonstrated capacity to build a platform company from first innovation to Phase 3 clinical trials – with a focus on maximizing shareholder value creation. Successfully raised >$120M in public and private/VC financing to facilitate rapid growth that includes open INDs with the US FDA and multiple clinical stage assets from Phase 1 to Phase 3 in vaccines and immune-oncology.
Dr. Holst is the founder of Hervolution and has a long-standing experience within immunology and has made pivotal discoveries in these fields. He has taken virus-vectored vaccines further by developing the first clinically effective genetic adjuvants. Peter Holst’s prior inventions are in clinical trials and licensed to GSK.
Dr. Holst is the founder of Hervolution and has a long-standing experience within immunology and has made pivotal discoveries in these fields. He has taken virus-vectored vaccines further by developing the first clinically effective genetic adjuvants. Peter Holst’s prior inventions are in clinical trials and licensed to GSK.
HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration
PDF version here Copenhagen, Denmark & New York, USA — 19 Dec 2023— HERVOLUTION Therapeutics ApS (‘HERVOLUTION’), a pioneering biotechnology company focused on developing novel
HERVOLUTION Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board
PDF version here • Prof Langer is a world-renowned scientist and entrepreneur who was a driving force behind Moderna’s mRNA nanoparticle Covid vaccine • Prof Langer has
New Research Reveals the Crucial Role of Endogenous Retrovirus Immunity in Tumor Immunity and Vaccine Development
A series of recent manuscripts by Skandorff et al., Daradoumis et al., and Ng et al. shed light on the significance of endogenous retrovirus immunity
Hervolution announces EUR 6M Seed financing with the participation of the European Innovation Council Fund to develop first-in-class cancer immunotherapy
Download PDF version here • Danish start-up developing immunotherapies designed to fight the tumors from within • Financing supports GMP and tox studies and will advance Hervolution’s first-in-class cancer immunotherapy into First-in-Human clinical trials • Strengthens team with appointment of industry
Hervolution has been awarded an EU grant to further explore the role of IPT001 in oncological immunotherapy approaches against hard to treat cancers
This initiative aims to advance our understanding of the potential applications of IPT001 in enhancing oncological immunotherapy, ultimately contributing to the development of more effective
Hervolution receives 2.5M EUR in funding through the European Innovation Council Accelerator
We are beyond proud to announce that Hervolution is one of just 65 European companies to receive funding through the European Innovation Council Accelerator. Being
